QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience

European Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2000, Pages 1-18

  De Ponti, F ^a   Poluzzi, E ^a   Montanaro, N ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adverse drug reactions; Cardiac arrhythmias; QT interval

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ASTEMIZOLE; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CISAPRIDE; DROPERIDOL; ERYTHROMYCIN; GREPAFLOXACIN; HALOFANTRINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; KETANSERIN; MACROLIDE; NEUROLEPTIC AGENT; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; PROBUCOL; PYRROLE DERIVATIVE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERTINDOLE; TACROLIMUS; TAMOXIFEN; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG;

DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG OVERDOSE; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK FACTOR; TORSADE DES POINTES;

EID: 0034074402     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050714     Document Type: Review

References (180)

1. 1. Zhang MQ (1997) Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 4: 171-184
2. 2. Kitayama H, Kiuchi K, Nejima J, Katoh T, Takano T, Hayakawa H (1999) Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 55: 259-262
3. 3. Lipicky RJ (1993) A viewpoint on drugs that prolong the QTc interval. Am J Cardiol 72: 53B-54B
4. 4. Thomas M, Maconochie JG, Fletcher E (1996) The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 41: 77-81
5. 5. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J (1991) QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83: 1888-1894
6. 6. Elming H, Holm E, Jun L, Torp-Pedersen C, Kober L, Kircshoff M, Malik M, Camm J (1998) The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 19: 1391-1400
7. 7. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE (1999) Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J 20: 278-284
8. 8. Roden DM, George ALJ (1997) Structure and function of cardiac sodium and potassium channels. Am J Physiol 273: H511-H525
9. 9. Fedida D, Chen FS, Zhang X (1998) The 1997 Stevenson Award Lecture. Cardiac K+ channel gating: cloned delayed rectifier mechanisms and drug modulation. Can J Physiol Pharmacol 76: 77-89
10. 10. Nattel S (1999) The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 10: 272-282
11. 11. Morgan TKJ, Sullivan ME (1992) An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem 29: 65-108
12. 12. Tonini M, De Ponti F, Di Nucci A, Crema F (1999) Review article: cardiac adverse effects of gastrointestinal prokinetics. Alim Pharmacol Ther 13: 1585-1591
13. 13. Crema F, Modini C, Croci T, Langlois M, De Ponti F (1999) Intestinal prokinesia by two esters of 4-amino-5-chloro-2-methoxybenzoic acid: involvement of 5-hydroxytryptamine-4 receptors and dissociation from cardiac effects in vivo. J Pharmacol Exp Ther 288: 1045-1052
14. 14. Davis AS (1998) The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol 17: 677-680
15. 15. Drici MD, Ebert SN, Wang WX, Rodriguez I, Liu XK, Whitfield BH, Woosley RL (1999) Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 34: 82-88
16. 16. Matsunaga T, Mitsui T, Harada T, Inokuma M, Murano H, Shibutani Y (1998) QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J Pharmacol Toxicol Methods 38: 201-209
17. 17. Matsunaga T, Harada T, Inokuma M, Mitsui T, Duffy PA, Aldridge A, Shibutani Y (1999) QT prolongation and torsades de pointes induced by an antifungal agent, D0870, in conscious dogs. Toxicology 132: 187-199
18. 18. Usui T, Sugiyama A, Ishida Y, Satoh Y, Sasaki Y, Hashimoto K (1998) Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels 13: 49-57
19. 19. D'Alonzo AJ, Zhu JL, Darbenzio RB (1999) Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe. Eur J Pharmacol 369: 57-64
20. 20. Ohmura T, Chachin M, Tarui S, Nagakura A, Igarashi T, Ikeda H, Ikegami K, Kitagawa H, Uchida S (1999) Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys. Eur J Pharmacol 378: 169-175
21. 21. Weissenburger J, Noyer M, Cheymol G, Jaillon P (1999) Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 29[suppl 3]: 190-196
22. 22. de Lorenzi FG, Bridal TR, Spinelli W (1994) Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 113: 527-535
23. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 24: 277-284
24. 24. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT (1999) Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 10: 836-843
25. 25. Michiels M, Van Peer A, Woestenborghs R, Heykants J (1986) Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 8: 53-62
26. 26. Sugiyama A, Aye NN, Katahira S, Saitoh M, Hagihara A, Matsubara Y, Hashimoto K (1997) Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 143: 89-95
27. 27. de Abajo FJ, Rodriguez LA (1999) Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 47: 307-313
28. 28. McMullin ST, Reichley RM, Watson LA, Steib SA, Frisse ME, Bailey TC (1999) Impact of a web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med 159: 2077-2082
29. 29. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA (1999) Three-and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 290: 429-438
30. 30. Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, Bastian G, Sarkany M, Schlapfer J, Giroux B, Leyvraz S (1998) Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 9: 1233-1242
31. 31. Stevenson JP, DeMaria D, Reilly D, Purvis JD, Graham MA, Lockwood G, Drozd M, O'Dwyer PJ (1999) Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother Pharmacol 44: 228-234
32. 32. Jaillon P, Morganroth J, Brumpt I, Talbot G (1996) Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 37[suppl A]: 161-167
33. 33. Anonymous (1997) Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CMPMP)
34. 34. Bonate PL, Russell T (1999) Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. J Clin Pharmacol 39: 349-358
35. 35. Spargias KS, Lindsay SJ, Kawar GI, Greenwood DC, Cowan JC, Ball SG, Hall AS (1999) QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur Heart J 20: 1158-1165
36. 36. Warner JP, Barnes TR, Henry JA (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93: 311-313
37. 37. Adamantidis MM, Kerram P, Dupuis BA (1994) In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 8: 391-407
38. 38. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18: 477-481
39. 39. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH (1996) Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 60: 543-553
40. 40. Bastecky J, Kvasnicka J, Vortel J, Zapletalek M, Hanus M, Kasparova V, Wasylisova V (1990) Suicidal ingestion of thioridazine as a cause of severe impairment of heart rhythm-polymorphic ventricular tachycardia (in Czech). Cesk Psychiatry 86: 264-268
41. 41. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T (1990) Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case (in Japanese). Kokyu To Junkan 38: 819-822
42. 42. Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013-2015
43. 43. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y (1998) Haloperidol-induced torsades de pointes. Chest 98: 482-484
44. 44. Lawrence KR, Nasraway SA (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531-537
45. 45. Metzger E, Friedman R (1993) Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 13: 128-132
46. 46. O'Brien JM, Rockwood RP, Suh KI (1999) Haloperidol-induced torsade de pointes. Ann Pharmacother 33: 1046-1050
47. 47. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM (1993) Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 119: 391-394
48. 48. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120: 968-974
49. 49. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J (1994) Droperidol causes a dose-dependent prolongation of the QT interval. Anesthes Analg 79: 983-986
50. 50. Desta Z, Kerbusch T, Flockhart DA (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65: 10-20
51. 51. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124: 168-175
52. 52. Rampe D, Murawsky MK, Grau J, Lewis EW (1998) The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286: 788-793
53. 53. Wagner KD, Fershtman M (1993) Potential mechanism of desipramine-related sudden death in children. Psychosomatics 34: 80-83
54. 54. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ (1999) Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128: 479-485
55. + current activation in guinea pig ventricular myocytes. Circ Res 74: 687-699
56. 56. Alderton HR (1995) Tricyclic medication in children and the QT interval: case report and discussion. Can J Psychiatry 40: 325-329
57. 57. Upward JW, Edwards JG, Goldie A, Waller DG (1988) Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 26: 399-402
58. 58. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J, Irvine MJ (1997) Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 17: 15-21
59. 59. Roy M, Dumaine R, Brown AM (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94: 817-823
60. 60. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso-PJJ, Lynch JJ (1995) Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76: 110-119
61. 61. Suessbrich H, Waldegger S, Lang F, Busch AE (1996) Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 385: 77-80
62. + channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292: 261-264
63. 63. Ming Z, Nordin C (1995) Terfenadine blocks time-dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 26: 761-769
64. + currents by antihistamines in rat ventricular myocytes. Biophys J 68: A113
65. 65. Liu S, Melchert RB, Kennedy RH (1997) Inhibition of L-type Ca2+ channel current in rat ventricular myocytes by terfenadine. Circ Res 81: 202-210
66. 66. Lu Y, Wang Z (1999) Terfenadine block of sodium current in canine atrial myocytes. J Cardiovasc Pharmacol 33: 507-513
67. Ks "swap". Biophys J 66: A210
68. 68. Berul CI, Morad M (1995) Regulation of potassium channels by nonsedating antihistamines. Circulation 91: 2220-2225
69. 69. Nishio M, Habuchi Y, Tanaka H, Morikawa J, Yamamoto T, Kashima K (1998) Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. J Pharmacol Exp Ther 287: 293-300
70. 70. Zhang MQ, Timmerman H (1993) Terfenadine: a mixture of equipotent antihistamine enantiomers without a clear 'isomeric ballast'. Pharm World Sci 15: 186-192
71. 71. Yang T, Prakash C, Roden DM, Snyders DJ (1995) Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 115: 267-274
72. 72. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT (1996) Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28: 1556-1561
73. 73. Chaufour S, Caplain H, Lilienthal N, L'heritier C, Deschamps C, Dubruc C, Rosenzweig P (1999) Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. Br J Clin Pharmacol 47: 515-520
74. 74. Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R (1999) Cardiovascular safety of fexofenadine HC1. Am J Cardiol 83: 1451-1454
75. 75. Pinto YM, van Gelder IC, Heeringa M, Crijns HJGM (1999) QT lengthening and life-threatening arrhytmias associated with fexofenadine. Lancet 353: 980
76. 76. Giraud T (1999) QT lengthening and arrhythmias associated with fexofenadine. Lancet 353: 2072-2073
77. 77. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, Affrime MB (1995) Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 58: 269-278
78. 78. Lacerda AE, Roy ML, Lewis EW, Rampe D (1997) Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 52: 314-322 (published erratum Mol Pharmacol 52: 754)
79. 79. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, Annunziato L (1998) Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 54: 113-121
80. 80. Crumb WJ (1999) Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Br J Pharmacol 126: 575-580
81. 81. Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh J, Thakker K, Chung M (1994) The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 56: 295-301
82. 82. Carmeliet E (1998) Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 124: 663-668
83. 83. Mishra A, Friedman HS, Sinha AK (1999) The effects of erythromycin on the electrocardiogram. Chest 115: 983-986
84. 84. Oberg KC, Bauman JL (1995) QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 15: 687-692
85. 85. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D (1997) A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes. A case report. Angiology 48: 821-826
86. 86. Gitler B, Berger LS, Buffa SD (1994) Torsades de pointes induced by erythromycin. Chest 105: 368-372
87. 87. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance BK (1996) QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 16: 663-674
88. 88. Daleau P, Lessard E, Groleau ME, Turgeon J (1995) Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91: 3010-3016
89. 89. Rampe D, Murawsky MK (1997) Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin. Naunyn Schmiedeberg's Arch Pharmacol 355: 743-750
90. 90. Stramba Badiale M, Nador F, Porta N, Guffanti S, Frediani M, Colnaghi C, Grancini F, Motta G, Carnelli V, Schwartz PJ (1997) QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 133: 108-111
91. 91. Stramba Badiale M, Guffanti S, Porta N, Frediani M, Beria G, Colnaghi C (1993) QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am Heart J 126: 740-742
92. 92. von Rosensteil NA, Adam D (1995) Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 13: 105-122
93. 93. van Haarst AD, van 't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF (1998) The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64: 542-546
94. 94. Lee KL, Jim MH, Tang SC, Tai YT (1998) QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 104: 395-396
95. 95. von Seidlein L, Jaffar S, Greenwood B (1997) Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 56: 494-497
96. 96. Monlun E, Pillet O, Cochard JF, Favarel GJ, le-Bras M (1993) Prolonged QT interval with halofantrine. Lancet 341: 1541-1542
97. 97. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ (1993) Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056
98. 98. Sheldon R, Duff H, Koshman ML (1995) Antiarrhythmic activity of quinine in humans. Circulation 92: 2944-2950
99. 99. Claessen FA, van-Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JC, Kager PA (1998) Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 3: 482-489
100. 100. White NJ, Looareesuwan S, Warrell DA (1983) Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol 5: 173-175
101. 101. Karbwang J, Thanavibul A, Molunto P, Na BK (1993) The pharmacokinetics of quinine in patients with hepatitis. Br J Clin Pharmacol 35: 444-446
102. 102. Po SS, Wang DW, Yang IC, Johnson JPJ, Nie L, Bennett PB (1999) Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33: 181-185
103. 103. Karbwang J, Davis TM, Looareesuwan S, Molunto P, Bunnag D, White NJ (1993) A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br J Clin Pharmacol 35: 265-271
104. 104. Ribeiro IR, Olliaro P (1998) Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) 58: 50-53
105. 105. van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ (1999) Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 55: 405-410
106. 106. Tinh Hien T, Day NP, Nguyen HP, Nguyen TH, Pham PL, Dinh XS, Ly VC, Ha V, Waller D, Peto TE, White NJ (1996) A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 335: 76-83
107. 107. Lode H, Vogel F, Elies W (1999) Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 21: 61-74
108. 108. Samaha FF (1999) QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107: 528-529
109. 109. Anonymous (1999) Transcript of the 67th meeting of the Anti-infective Drugs Advisory Committee (October 21, 1999). FDA internet site
110. 110. Demolis JL, Charransol A, Funck-Brentano C, Jaillon P (1996) Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 41: 499-503
111. 111. Lipsky BA, Dorr MB, Magner DJ, Talbot GH (1999) Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. Clin Ther 21: 148-159
112. 112. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH (1999) The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther 21: 1171-1181
113. 113. Adamantidis MM, Dumotier BM, Caron JF, Bordet R (1998) Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol 12: 70-76
114. 114. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI (1998) Proarrhythmia associated with cisapride in children. Pediatrics 101: 1053-1056
115. 115. Benatar A, Feenstra A, Decraene T, Vandenplas Y (1999) Cisapride and proarrhythmia in childhood. Pediatrics 103: 856-857
116. 116. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B (1998) Effects of cisapride on QT interval in children. J Pediatr 133: 51-56
117. 117. Bernardini S, Semama DS, Huet F, Sgro C, Gouyon JB (1997) Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed 77: F241-F243
118. 118. Lupoglazoff JM, Bedu A, Faure C, Denjoy I, Casasoprana A, Cezard JP, Aujard Y (1997) Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson. Arch Pediatr 4: 509-514
119. 119. Rampe D, Roy ML, Dennis A, Brown AM (1997) A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417: 28-32
120. 120. Mohammad S, Zhou Z, Gong Q, January CT (1997) Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273: H2534-H2538
121. 121. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J (1998) Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97: 204-210
122. 122. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Qiu MR, Breit SN, Campbell TJ (1999) Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 128: 444-450
123. 123. Ikeda T (1994) QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabetes Metab 20: 565-567
124. 124. Shaffer P, Pelzmann B, Bernhart E, Lang P, Mächler H, Rigler B, Koidl B (1999) The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br J Pharmacol 128: 1175-1180
125. 125. Rosati B, Rocchetti M, Zaza A, Wanke E (1998) Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 440: 125-130
126. 126. Arfiero S, Ometto R, Vincenzi M (1999) Ketanserin induced QT prolongation and torsade de pointes. Giornale Italiano di Cardiologia 20: 869-872
127. 127. Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler KU, Just H (1989) Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 63: 826-832
128. 128. Aldariz AE, Romero H, Baroni M, Baglivo H, Esper RJ (1986) QT prolongation and torsade de pointes ventricular tachycardia produced by ketanserin. Pacing Clin Electrophysiol 9: 836-841
129. 129. Zhang ZH, Boutjdir M, El-Sherif N (1994) Ketanserin inhibits depolarization-activated outward potassium current in rat ventricular myocytes. Circ Res 75: 711-721
130. 130. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J (1999) A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 29[suppl 3]: 200-205
131. 131. Paserchia LA, Hewett J, Woosley RL (1994) Effect of ketoconazole on QTc. Clin Pharmacol Ther 55: 146
132. 132. Dumaine R, Roy ML, Brown AM (1998) Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 286: 727-735
133. 133. Gras J, Llenas J, Palacios JM, Roberts DJ (1996) The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 119: 187-188
134. 134. Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne-PE J, Wortham DC (1994) Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105: 389-395
135. 135. Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, Chernoff SB (1984) Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol 26: 735-739
136. 136. Romics L, Littmann L, Laszlo Z, Fenyvesi T (1988) The effects of probucol on QT/QS2 relation and systolic time intervals. Int J Cardiol 19: 303-308
137. 137. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M (1993) Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 45: 47-52
138. 138. Tamura M, Ueki Y, Ohtsuka E, Oribe M, Seita M, Oribe K, Ito M (1994) Probucol-induced QT prolongation and syncope. Jpn Circ J 58: 374-377
139. 139. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH (1996) Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 131: 1184-1191
140. 140. Johnson MC, So S, Marsh JW, Murphy AM (1992) QT prolongation and torsades de pointes after administration of FK506. Transplantation 53: 929-930
141. 141. Sawabe T, Mizuno S, Gondo H, Maruyama T, Niho Y (1997) Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. Transplantation 64: 182-183
142. 142. Calandra S (1998) Sinus arrest during tacrolimus treatment: was the QT interval prolonged? Transplantation 66: 402-404
143. 143. Kodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM (1998) QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 66: 535-537
144. 144. duBell WH, Wright PA, Lederer WJ, Rogers TB (1997) Effect of the immunosupressant FK506 on excitation-contraction coupling and outward K+ currents in rat ventricular myocytes. J Physiol (Lond) 501: 509-516
145. 145. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JRJ, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, Jordan VC (1997) A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3: 1109-1115
146. 146. Trump DL, Smith DC, Ellis PG, Rogers MP, Schuld SC, Winer EP, Panella TJ, Jordan VC, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816
147. 147. Liu XK, Katchman A, Ebert SN, Woosley RL (1998) The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287: 877-883
148. 148. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338: 344-345
149. 149. Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-580
150. 150. Hartigan-Go K, Bateman DN, Daly AK, Thomas SH (1996) Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 60: 89-98
151. 151. Jones SE, Ogura T, Shuba LM, McDonald TF (1998) Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Br J Pharmacol 125: 1138-1143
152. 152. Shuba LM, Kasamaki Y, Jones SE, Ogura T, McCullough JR, McDonald TF (1999) Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. J Pharmacol Exp Ther 290: 1417-1426
153. 153. Jones SE, Kasamaki Y, Ogura T, Shuba LM, McCullough JR, McDonald TF (1999) Inhibition of cardiac inward-rectifier K+ current by terodiline. Eur J Pharmacol 370: 319-327
154. 154. Pressler ML, Warner MR, Rubart M, Rardon DP, Zipes DP (1995) In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium. J Cardiovasc Electrophysiol 6: 443-454
155. 155. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L (1996) Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131: 472-480
156. 156. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LRJ (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52: 231-238
157. 157. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena-LR J (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790
158. 158. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A (1992) Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J 13: 1002-1003
159. 159. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269: 1513-1518
160. 160. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR (1993) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 33: 1201-1206
161. 161. Honig PK, Wortham DC, Lazarev A, Cantilena LR (1996) Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 36: 345-351
162. 162. Sakemi H, VanNatta B (1993) Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 125: 1436-1438
163. 163. Hsieh MH, Chen SA, Chiang CE, Tai CT, Lee SH, Wen ZC, Chang MS (1996) Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol 54: 85-88
164. 164. Tsai WC, Tsai LM, Chen JH (1997) Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 96: 144-146
165. 165. Adamantidis MM, Lacroix DL, Caron JF, Dupuis BA (1995) Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. J Cardiovasc Pharmacol 26: 319-327
166. 166. Woosley RL, Chen Y, Freiman JP, Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. JAMA 269: 1532-1536
167. 167. Roy M, Dumaine R, Brown AM (1996) HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94: 817-823
168. 168. Ducic I, Ko CM, Shuba Y, Morad M (1997) Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 30: 42-54
169. 169. Sorkin EM, Heel RC (1985) Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 34-56
170. 170. Heykants J, Van Peer A, Woestenborghs R, Jageneau A, Vanden Bussche (1986) Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. Drug Dev Res 8: 71-78
171. 171. Honig PK, Wortham DC, Zamani K, Cantilena LR (1994) Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 7: 148-156
172. 172. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P (1993) Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 45: 191-193
173. 173. Crane JK, Shih HT (1993) Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 95: 445-446
174. 174. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL (1996) Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 59: 383-388
175. 175. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS (1997) The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52: 311-315
176. 176. Lefebvre RA, Van Peer A, Woestenborghs R (1997) Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol 43: 319-322
177. 177. Goodman LS, Gilman A (1996) The pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York
178. 178. Slater JW, Zechnich AD, Haxby DG (1999) Second-generation antihistamines: a comparative review. Drugs 57: 31-47
179. 179. Knight BP, Pelosi F, Michaud GF, Strickberger SA, Morady F (1999) Clinical consequences of electrocardiographic artifact mimicking ventricular tachycardia. N Engl J Med 341: 1270-1274
180. 180. Murakawa Y, Yamashita T, Ajiki K, Sezaki K, Omata M (1998) Ostensible day-night difference of QT prolongation during long-term treatment with antiarrhythmic drugs: reappraisal of the law of "regression to the mean". J Cardiovasc Pharmacol 32: 62-65